American Vein and Lymphatic Society Revenue and Competitors
Estimated Revenue & Valuation
- American Vein and Lymphatic Society's estimated annual revenue is currently $8.6M per year.
- American Vein and Lymphatic Society's estimated revenue per employee is $216,000
Employee Data
- American Vein and Lymphatic Society has 40 Employees.
- American Vein and Lymphatic Society grew their employee count by -9% last year.
American Vein and Lymphatic Society's People
Name | Title | Email/Phone |
---|
American Vein and Lymphatic Society Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $13.9M | 57 | -30% | N/A | N/A |
#2 | $4.9M | 26 | -4% | N/A | N/A |
#3 | $142.1M | 421 | 8% | N/A | N/A |
#4 | $9.9M | 46 | 5% | N/A | N/A |
#5 | $165.7M | 491 | 5% | N/A | N/A |
#6 | $607.1M | 1606 | 5% | N/A | N/A |
#7 | $7.8M | 36 | 6% | N/A | N/A |
#8 | $10.4M | 48 | -11% | N/A | N/A |
#9 | $52M | 175 | 7% | N/A | N/A |
#10 | $529.2M | 1400 | 10% | N/A | N/A |
What Is American Vein and Lymphatic Society?
The American Vein & Lymphatic Society (AVLS) is the oldest and largest association in the United States for physicians and allied health professionals dedicated to the diagnosis and treatment of venous and lymphatic disease. Comprised of more than 2,000 members, the AVLS is a forum to exchange medical knowledge, best practices and the latest treatment options, as well as offering continuing education and training aimed at improving the quality of patient care. For more than 30 years, the AVLS has been an advocate for the advancement of vein and lymphatic care through education, advocacy and research. For more information, please visit the AVLS online at www.phlebology.org.
keywords:N/AN/A
Total Funding
40
Number of Employees
$8.6M
Revenue (est)
-9%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $7.8M | 40 | 8% | N/A |
#2 | $4.6M | 40 | N/A | N/A |
#3 | $4.6M | 40 | N/A | N/A |
#4 | $6.6M | 40 | -26% | N/A |
#5 | $8.6M | 40 | 14% | N/A |